The next generation
in tissue sealants
and hemostatic agents
A breakthrough technology to transform how surgeons seal tissues and control bleeding for better and safer care
Sealantium Medical announces the successful completion of its multicenter Phase I/II clinical trial.
Addressing surgical sealing and bleeding control challenges
Surgeons today seek easy-to-use products to stop bleeding during surgery and efficiently seal tissues with minimal infection risk. Hemostatic agents that shorten time to blood clotting are often used for bleeding control where conventional methods are ineffective or impractical. Commonly applied fibrin sealants (FS) have today proven efficaciousness in open surgery.
Yet, during more intense bleeding, these topically applied agents, have marginal effects, getting washed away by strong blood flow. They also cannot be used in minimally invasive surgery.
At Sealantium Medical, we have solved this problem.
Introducing the sFilm-FS™:
A leap forward in biosurgical design
hemostatic and
sealing capabilities
sealing for better
performance
& affordable
minimally
invasive use
fluid including
blood
Groundbreaking hemostatic
and sealing technology
Now for both open and
minimally invasive surgery
We have developed a patented multi-acting technology that uniquely enables hemostasis and sealing.
This is exemplified in our flagship product, the sFilm-FS™, which comprises a biodegradable and biocompatible, non-permeable polymeric film containing Fibrin Sealant. This polymeric film uniquely enables sealing capabilities alongside accelerating fluid coagulation and site adhesion.
As a result of this novel mechanism of action, substantially less Fibrin Sealant is needed lowering costs and accelerating speed of sealing (<2min) for improved performance.
Following a successful proof of concept in laparoscopic surgery, the sFilm-FS™’s flexible nature will make it the first product of its kind for use in minimally invasive surgery. Its diverse tissue sealing capabilities can also be applied with benefit in many clinical scenarios.
About Sealantium Medical
Sealantium Medical is a biosurgery company focused on the development of proprietary next generation tissue sealants and hemostatic agents for patients undergoing surgery.
The company is led by a highly professional and experienced team of healthcare entrepreneurs and senior industry players with a track record of success in developing similar products.
Successful preclinical data has demonstrated efficacy and usability of the sFilm-FS™. Promising early clinical results show safety and a faster performance in controlling liver bleeding during surgery than the market leading product.
sFilm-FS™ will be the first, innovative hemostatic and sealing patch to address the more than $1 billion surgical sealant market in almost a decade.
Our Management
Prof. Orgad Laub
CEO & Founder
Former VP, R&D, Omrix (J&J) R&D Manager Interpharm (Serono/Merck) VP at YEDA (Tech transfer office of the Weizmann Institute) Prof of Virology at the Weizmann Institute
Dr. Chris Lamb
Business Developer & Co-Founder
CEO & Founder, Prothya BioSolutions SVP & COO, American Red Cross Blood Plasma Unit BoD, ProFibrix (The Medicines Company) Founder, BioSolutions LLC (Consultancy for leading biologics companies: Omrix, Takeda, Kedrion, others)
Dr. Sara Horn
Regulatory Affairs
VP Clinical and Regulatory Affairs, Omrix (J&J) VP Product Development, Vascular Biogenics RA Manager, Perio Products RA Associate, Interpharm (Serono/Merck)
Issar Ash
Quality Assurance
QA Manager, Interpharm (Serono/Merck) Consultant to various biotechnology companies Over 30 years of experience in QA and GMP-related issues
Yonatan Naveh
VP Finance
Corporate Controller: SCP Vitalife & Targetech Innovation Center. Auditor: KPMG Somekh Chaikin CPA (Israel) & B.A. in Accounting & Economics, Ben Gurion University
Eran Cohen
Project Manager
MSc in Chemistry with specialization in Biomedical polymers Developed novel polymers in collaboration with Prof Daniel Cohn at the Hebrew University
Adi Richter
Legal Counsel
